Recombinant Human ACE2 protein (hFc Tag)

ED50

36-146 ng/mL

Species

Human

Purity

>90 %, SDS-PAGE

GeneID

59272

Accession

Q9BYF1

Cat No : Eg0124

Print datasheet

Synonyms

ACE2, ACE-2, ACEH



Technical Specifications

Purity >90 %, SDS-PAGE
Endotoxin Level <1.0 EU/μg protein, LAL method
Biological Activity
Immobilized SARS-CoV-2 Spike RBD (Myc tag, His tag) at 2 μg/mL (100 μL/well) can bind Human ACE2 (hFc tag) with a linear range of 36-146 ng/mL.
Source HEK293-derived Human ACE2 protein Gln18-Ser740 (Accession# Q9BYF1) with a human IgG1 Fc tag at the N-terminus.
Predicted Molecular Mass 109.6 kDa
SDS-PAGE 110-140 KDa, reducing (R) conditions
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Angiotensin-converting enzyme 2 (ACE2), a critical regulator of the renin-angiotensin system (RAS), belongs to the peptidase M2 family. It plays an important role in cardiovascular homeostasis by regulating vascular tone, fluid, and electrolyte balance. ACE2 functions as a carboxymonopeptidase hydrolyzing the cleavage of a single C-terminal residue from Angiotensin-II (Ang-II), the key peptide hormone of RAS, to form Angiotensin-(1-7) (Ang-(1-7)), which binds to the G-protein-coupled Mas receptor and activates signaling pathways that counteract the pathways activated by Ang-II. ACE2 is expressed in a variety of tissues, including the kidneys, testes, heart, and intestines, and is particularly enriched in lung epithelium. Recent studies have shown that increased ACE2 expression is likely to help prevent secondary fibrosis changes following COVID-19 pneumonia.

References:

1. Li Q. et al. (2020). Clin Sci (Lond). 134:2581-2595. 2. Li Y. et al. (2020). Biochem Biophys Res Commun. 526:947-952. 3. Hikmet F. et al. (2020). Mol Syst Biol. 16:e9610. 4. Chaudhry F. et al. (2020). Open Heart. 7:e001424.